A Phase II Trial of Recombinant Tumor Necrosis Factor in Patients with Adenocarcinoma of the Pancreas: A Southwest Oncology Group Study
作者:
Thomas Brown,
Phyllis Goodman,
Thomas Fleming,
John Macdonald,
Evan Hersh,
Thomas Braun,
期刊:
Journal of Immunotherapy
(OVID Available online 1991)
卷期:
Volume 10,
issue 5
页码: 376-378
ISSN:1524-9557
年代: 1991
出版商: OVID
关键词: Pancreatic adenocarcinoma;Recombinant tumor necrosis factor
数据来源: OVID
摘要:
Summary:Twenty-two evaluable patients with advanced adenocarcinoma of the pancreas, but without prior chemotherapy or immunotherapy, received recombinant tumor necrosis factor (rTNF). rTNF was given as an intravenous infusion over 30 min daily x 5, every 14 days, at a starting dose of 150 (μg/m2/ day. Toxicities included fevers/rigors, nausea/vomiting/anorexia, flu-like symptoms, hypotension, hyperglycemia, anemia, coagulopathy, hepatotoxicity, and hypertriglyceridemia. Laboratory evidence of disseminated intravascular coagulopathy occurred in 11 patients, with only 3 of these patients having clinical manifestations. Two patients suffered from pulmonary emboli. The high incidence of coagulopathy was felt to be, at least in part, disease related. No objective responses were observed with a 95% confidence interval of 0-15%.
点击下载:
PDF
(99KB)
返 回